Myomo, Inc. (MYO)
Myomo, Inc. is a wearable medical robotics company specializing in myoelectric orthotics for individuals with neuromuscular disorders. Their flagship product, MyoPro, enhances upper limb function for those with weakened or paralyzed arms.
Company Overview
Myomo, Inc. pioneers wearable medical robotics with MyoPro, a myoelectric orthosis empowering individuals with neuromuscular disorders to regain upper limb function and independence, targeting a significant unmet need in rehabilitation and assistive technology with a $0.03B market cap.
Investment Thesis
Myomo presents a compelling investment opportunity within the medical device sector, driven by its innovative MyoPro orthosis and a growing market for assistive technologies. The company's focus on addressing upper limb paralysis in individuals with neuromuscular disorders positions it to capitalize on a significant unmet need. Key value drivers include expanding sales through the Veterans Health Administration, rehabilitation hospitals, and strategic partnerships with orthotics and prosthetics providers. Growth catalysts include increasing awareness of MyoPro's benefits among healthcare professionals and patients, securing additional insurance coverage, and expanding into new geographical markets. While the company currently operates with a negative profit margin of -28.9%, the high gross margin of 66.6% indicates the potential for profitability as sales volume increases. Investors should consider Myomo's potential for long-term growth and its positive impact on patients' lives.
Key Highlights
- Market Cap of $0.03B reflects the company's current valuation and growth potential within the medical device market.
- Gross Margin of 66.6% indicates strong pricing power and efficient production of MyoPro orthotics.
- Negative P/E Ratio of -2.82 suggests the company is currently not profitable, but reflects investment in growth and development.
- Beta of 1.16 indicates the stock is slightly more volatile than the market, reflecting its growth-oriented nature.
- Focus on the Veterans Health Administration provides a stable revenue stream and access to a large patient population.
Competitors
Strengths
- Innovative MyoPro technology addresses a significant unmet need.
- Established presence within the Veterans Health Administration.
- High gross margin indicates strong pricing power.
- Focus on improving patient outcomes and quality of life.
Weaknesses
- Currently operating with a negative profit margin.
- Limited brand awareness compared to larger medical device companies.
- Reliance on third-party distributors and O&P providers.
- Relatively small market capitalization.
Catalysts
- Upcoming: Expansion of insurance coverage for MyoPro, increasing accessibility for patients.
- Ongoing: Continued growth in sales through the Veterans Health Administration.
- Upcoming: Launch of next-generation MyoPro orthotics with enhanced features.
- Ongoing: Strategic partnerships with leading orthotics and prosthetics providers.
- Ongoing: Positive clinical trial results demonstrating the effectiveness of MyoPro.
Risks
- Potential: Competition from larger medical device companies with greater resources.
- Potential: Technological advancements that could render MyoPro obsolete.
- Ongoing: Dependence on third-party distributors and O&P providers.
- Potential: Changes in healthcare regulations and reimbursement policies.
- Ongoing: Economic downturn affecting patient affordability.
Growth Opportunities
- Expansion within the Veterans Health Administration (VHA): Myomo has established a presence within the VHA, providing MyoPro to veterans with upper limb paralysis. Expanding this relationship through increased awareness and adoption within VHA hospitals and clinics represents a significant growth opportunity. The VHA serves a large patient population with neuromuscular disorders, offering a stable and recurring revenue stream for Myomo. Securing additional contracts and expanding the range of covered conditions within the VHA can drive substantial growth in the coming years.
- Strategic Partnerships with Orthotics and Prosthetics (O&P) Providers: Collaborating with O&P providers is crucial for reaching patients and facilitating the fitting and training process for MyoPro. Establishing strategic partnerships with leading O&P clinics across the United States can expand Myomo's market reach and enhance its distribution network. These partnerships provide access to established patient referral pathways and expertise in orthotic and prosthetic care, accelerating adoption and improving patient outcomes. This growth driver can be realized within the next 1-3 years.
- Securing Broader Insurance Coverage: Obtaining broader insurance coverage for MyoPro is essential for increasing affordability and accessibility for patients. Working with insurance companies to demonstrate the clinical and economic benefits of MyoPro can lead to expanded coverage policies. This involves conducting clinical trials, publishing research findings, and engaging with payers to highlight the value proposition of MyoPro. Successful expansion of insurance coverage can significantly increase the addressable market and drive sales growth over the next 2-5 years.
- Development of Next-Generation Myoelectric Orthotics: Investing in research and development to create next-generation myoelectric orthotics can enhance Myomo's product offerings and maintain its competitive edge. This includes incorporating advanced sensor technology, improving the device's functionality and comfort, and expanding its applications to address a wider range of neuromuscular conditions. Continuous innovation and product development are crucial for sustaining long-term growth and attracting new customers. This is an ongoing effort with potential for incremental improvements and new product launches in the coming years.
- Geographic Expansion into International Markets: Expanding into international markets represents a significant growth opportunity for Myomo. Identifying countries with a high prevalence of neuromuscular disorders and a favorable regulatory environment can drive international sales. This involves establishing partnerships with local distributors, adapting the MyoPro device to meet local standards, and conducting clinical trials to demonstrate its effectiveness in diverse populations. International expansion can diversify revenue streams and unlock new growth opportunities over the next 3-5 years.
Opportunities
- Expanding insurance coverage for MyoPro.
- Developing next-generation myoelectric orthotics.
- Geographic expansion into international markets.
- Strategic partnerships with leading rehabilitation centers.
Threats
- Competition from established medical device companies.
- Technological advancements that could render MyoPro obsolete.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturn affecting patient affordability.
Competitive Advantages
- Proprietary myoelectric technology in the MyoPro orthosis.
- Established relationships with the Veterans Health Administration.
- Specialized expertise in wearable medical robotics.
- Strong gross margin indicating pricing power.
About
Myomo, Inc., founded in 2004 and headquartered in Boston, Massachusetts, is a medical robotics company focused on designing, developing, and producing myoelectric orthotics. The company's core product, MyoPro, is a myoelectric-controlled upper limb brace that supports and improves the functionality of weak or paralyzed arms. This innovative technology enables individuals with neuromuscular conditions to perform activities of daily living more effectively. MyoPro is designed for adults and adolescents affected by conditions such as brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. Myomo distributes its products through a network of orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals, and distributors. The company's mission is to restore independence and improve the quality of life for individuals with upper limb paralysis through advanced medical robotics. Myomo operates primarily in the United States, addressing a critical need for assistive technology in the rehabilitation and healthcare sectors. The company's focus on innovation and patient-centric solutions positions it as a key player in the wearable medical robotics market.
What They Do
- Designs and develops myoelectric orthotics.
- Produces the MyoPro, an upper limb brace controlled by myoelectric signals.
- Provides assistive technology for individuals with neuromuscular disorders.
- Improves functional activities of daily living for patients with weak or paralyzed arms.
- Sells products to orthotics and prosthetics providers.
- Partners with the Veterans Health Administration to provide MyoPro to veterans.
- Distributes products through rehabilitation hospitals and distributors.
Business Model
- Direct sales to orthotics and prosthetics providers.
- Sales through the Veterans Health Administration.
- Distribution through rehabilitation hospitals.
- Partnerships with distributors to expand market reach.
Industry Context
Myomo operates within the medical device industry, specifically in the market for wearable robotics and assistive technologies. This sector is experiencing growth driven by an aging population, increasing prevalence of neurological disorders, and advancements in robotics and sensor technology. The competitive landscape includes companies developing exoskeletons, orthotics, and prosthetics. Myomo differentiates itself with its myoelectric-controlled MyoPro orthosis, designed specifically for upper limb paralysis. The industry is characterized by stringent regulatory requirements, technological innovation, and a focus on improving patient outcomes. The global market for medical robotics is projected to reach billions of dollars in the coming years, presenting significant growth opportunities for companies like Myomo.
Key Customers
- Individuals with neuromuscular disorders (stroke, brachial plexus injury, etc.).
- Orthotics and prosthetics providers.
- Veterans Health Administration.
- Rehabilitation hospitals.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10M | -$4M | $0.00 |
| Q2 2025 | $10M | -$5M | $0.00 |
| Q1 2025 | $10M | -$3M | $0.00 |
| Q4 2024 | $12M | $-260,080 | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Myomo, Inc. (MYO) stock price: $1.08 (+0.09, +9.09%)
Why Bull
- •Buzz around Myomo's potential partnerships is growing, hinting at broader market reach.
- •The company's focus on personalized medical devices resonates well with the current trend towards patient-centric healthcare.
- •Recent insider buying activity suggests confidence in Myomo's long-term prospects.
- •Positive community sentiment indicates a belief in Myomo's ability to disrupt the assistive technology space.
Why Bear
- •Skepticism remains regarding the scalability of Myomo's custom-fit approach.
- •The competitive landscape in assistive robotics is intensifying, posing challenges to Myomo's market share.
- •Concerns exist about the company's ability to secure consistent reimbursement from insurance providers.
- •Some community members question whether Myomo can maintain its innovative edge given resource constraints.
Latest News
-
Earnings Scheduled For November 10, 2025
benzinga · Nov 10, 2025
-
Earnings Scheduled For August 11, 2025
benzinga · Aug 11, 2025
-
Earnings Scheduled For May 7, 2025
benzinga · May 7, 2025
-
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga · Aug 24, 2023
Technical Analysis
Rationale
AI-generated technical analysis for MYO including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Myomo, Inc. (MYO) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for MYO.
Make a Prediction
Set your price target for Myomo, Inc. (MYO), choose a timeframe, and track your prediction accuracy.
Current price: $1.08
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MYO.
Price Targets
Wall Street price target analysis for MYO.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 8/100
Revenue grew 69.2% YoY, showing strong top-line momentum well above industry average.
-
Gross Margin 10/100
Gross margin of 66.6% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates MYO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Myomo, Inc. do?
Myomo, Inc. is a wearable medical robotics company that specializes in the design, development, and production of myoelectric orthotics. Their primary product, MyoPro, is a myoelectric-controlled upper limb brace designed to support and improve the function of weak or paralyzed arms. This technology helps individuals with neuromuscular disorders, such as those resulting from stroke, brachial plexus injury, or spinal cord injury, to perform daily activities more effectively. Myomo sells its products through orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals, and distributors, focusing on improving the quality of life for patients with upper limb paralysis.
Is MYO stock a good buy?
MYO stock represents a speculative investment opportunity with high growth potential but also significant risks. The company's innovative MyoPro technology and established presence within the Veterans Health Administration are positive factors. However, the company's negative profit margin and small market capitalization warrant caution. Investors should carefully consider the company's growth prospects, competitive landscape, and financial performance before investing. While the high gross margin suggests potential for future profitability, the company needs to demonstrate sustainable revenue growth and cost management to justify a positive investment outlook. A balanced approach considering both the potential upside and inherent risks is essential.
What are the main risks for MYO?
Myomo faces several key risks, including competition from larger medical device companies with greater resources, the potential for technological advancements to render MyoPro obsolete, and dependence on third-party distributors and O&P providers. Changes in healthcare regulations and reimbursement policies could also negatively impact the company's revenue. Additionally, an economic downturn could affect patient affordability and demand for MyoPro. The company's current financial performance, including its negative profit margin, also poses a risk. Investors should carefully assess these risks and consider their potential impact on Myomo's future performance.
Is MYO a good stock to buy?
Whether MYO is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the MYO MoonshotScore?
The MoonshotScore for MYO is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is MYO data updated?
MYO stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to MYO is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for MYO?
Growth catalysts for Myomo, Inc. (MYO) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Myomo, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are MYO's main competitors?
Myomo, Inc. (MYO) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether MYO has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about MYO?
Wall Street analyst coverage for MYO includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is MYO's market cap?
Market capitalization (market cap) for MYO is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows MYO's current market cap alongside enterprise value and other valuation metrics.
How has MYO stock performed recently?
MYO's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing MYO's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in MYO?
Key risk categories for MYO include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures MYO's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling MYO?
Insider trading activity for MYO tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is MYO a good stock for beginners?
Myomo, Inc. (MYO) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is MYO for first-time investors?
Every stock carries risk, including Myomo, Inc. (MYO). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like MYO.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Market analysis is based on current industry trends and forecasts.
- This analysis is for informational purposes only and does not constitute investment advice.